BioLineRx (BLRX) Beginning Cash Balance (2021 - 2025)

BioLineRx's Beginning Cash Balance history runs 5 years deep, the most recent figure standing at -$1.1 million for Q4 2025.

• In Q4 2025, Beginning Cash Balance rose 90.49% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$4.5 million (up 68.84% YoY), while the FY2025 annual figure was -$4.5 million, up 68.84% from the prior year.
• Beginning Cash Balance was -$1.1 million for Q4 2025 at BioLineRx, down from -$1.1 million in the prior quarter.
• In the past five years, Beginning Cash Balance ranged from a high of -$741000.0 in Q4 2023 to a low of -$12.0 million in Q4 2024.
• Historically, Beginning Cash Balance has averaged -$1.6 million across 5 years, with a median of -$904500.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Beginning Cash Balance sank 1515.65% in 2024, then surged 90.49% in 2025.
• A 5-year view of Beginning Cash Balance shows it stood at -$854000.0 in 2021, then fell by 19.44% to -$1.0 million in 2022, then climbed by 27.35% to -$741000.0 in 2023, then tumbled by 1515.65% to -$12.0 million in 2024, then soared by 90.49% to -$1.1 million in 2025.
• The last three Beginning Cash Balance figures came in at -$1.1 million (Q4 2025), -$1.1 million (Q3 2025), and -$1.1 million (Q2 2025), per Business Quant data.